SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
AGIO reported Third Quarter 2026 results. The stock moved -9.9% on the print.
AGIOearnings

Earnings reactions, page 7

Agios Pharmaceuticals, Inc. (AGIO) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $55.4 million in the third quarter of 2026.
  • U.S. net revenue for mitapivat was $48.7 million and ex-U.S. net revenue was $6.6 million in the third quarter of 2026.
  • Research and Development (R&D) expenses were $73.5 million for the third quarter of 2026.
  • Selling, General and Administrative (SG&A) expenses were $56.5 million for the third quarter of 2026.
  • Cash, cash equivalents, and marketable securities were $907.0 million as of September 30, 2026.

Guidance

  • Agios is targeting non-GAAP profitability in 2028.

Price and volatility reaction

The stock moved -9.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +0.5 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release31.382026-11-04
Close after release28.272026-11-05
Realised move-9.9%close to close
30d ATM IV change+0.5 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →